 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE:ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates ADCs for patients with hematological malignancies and solid tumors, announced today that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Access Event taking place January 11-14, 202 